UA106907C2 - Стабілізована фармацевтична композиція - Google Patents

Стабілізована фармацевтична композиція

Info

Publication number
UA106907C2
UA106907C2 UAA201211360A UAA201211360A UA106907C2 UA 106907 C2 UA106907 C2 UA 106907C2 UA A201211360 A UAA201211360 A UA A201211360A UA A201211360 A UAA201211360 A UA A201211360A UA 106907 C2 UA106907 C2 UA 106907C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
stabilized pharmaceutical
disease
stabilized
pregabalin
Prior art date
Application number
UAA201211360A
Other languages
English (en)
Russian (ru)
Inventor
Камала С. Ядав
Аміта П. Сурана
Санджавані А. Кукарні
Рашмі Р. Прасейд
Original Assignee
Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг filed Critical Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Publication of UA106907C2 publication Critical patent/UA106907C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід належить до стабілізованої твердої фармацевтичної композиції, що містить прегабалін та дисахарид, який вибраний з ізомальту, лактилолу, мальтилолу або їх суміші, як стабілізатор. Стабілізована тверда фармацевтична композиція, згідно з даним винаходом, застосовується для лікування ряду захворювань, таких як епілепсія, хвороба Альцгеймера або хвороба Паркінсона.
UAA201211360A 2010-03-01 2011-03-01 Стабілізована фармацевтична композиція UA106907C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1000120A HU230031B1 (hu) 2010-03-01 2010-03-01 Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
PCT/HU2011/000019 WO2011107812A2 (en) 2010-03-01 2011-03-01 Stabilized pharmaceutical composition

Publications (1)

Publication Number Publication Date
UA106907C2 true UA106907C2 (uk) 2014-10-27

Family

ID=89989589

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201211360A UA106907C2 (uk) 2010-03-01 2011-03-01 Стабілізована фармацевтична композиція

Country Status (10)

Country Link
US (1) US8968780B2 (uk)
EP (1) EP2542229A2 (uk)
CN (1) CN102869350A (uk)
BR (1) BR112012022255A2 (uk)
EA (1) EA021719B1 (uk)
HU (1) HU230031B1 (uk)
MA (1) MA34090B1 (uk)
UA (1) UA106907C2 (uk)
WO (1) WO2011107812A2 (uk)
ZA (1) ZA201207375B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
WO2019009927A1 (en) * 2017-07-06 2019-01-10 Adorus Pharmaceuticals Llc MIXTURE COMPOSITIONS FOR ORAL ADMINISTRATION AS POWDER AND / OR SUSPENSION WITH RAPID DISSOLUTION
JP6504638B1 (ja) * 2018-05-31 2019-04-24 武田テバファーマ株式会社 錠剤及びその製造方法
CN110613689A (zh) * 2018-06-19 2019-12-27 北京万全德众医药生物技术有限公司 一种含有两亲性聚合物-普瑞巴林复合物的口崩片
WO2024165618A1 (en) 2023-02-07 2024-08-15 Kinast Lasse An immediate-release tablet of pregabalin with an increased percentage api content

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
DE9321600U1 (de) 1993-05-06 2000-04-06 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt, 68165 Mannheim Süssungsmittel
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
CN1303991C (zh) 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
KR100669280B1 (ko) 1998-05-15 2007-01-17 워너-램버트 캄파니 엘엘씨 감마-아미노부티르산 유도체 포함 고상 조성물 및 그의제조 방법
FR2781793B1 (fr) 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
NZ529173A (en) 2001-05-25 2005-07-29 Warner Lambert Co Stable liquid pharmaceutical composition comprising a GABA analog i.e. gabapentin or pregabalin, and a polyhydric alcohol e.g. glycerol, xylitol, sorbitol, mannitol
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
WO2005051384A1 (en) 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
EP1543831A1 (en) 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
ITMI20041447A1 (it) 2004-07-20 2004-10-20 Zambon Spa Composizione farmaceutica comprendente gabapentina
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
CN1827590A (zh) * 2006-04-14 2006-09-06 北京润德康医药技术有限公司 一种普瑞巴林新晶型、制备方法及其药用组合物
DE102006030642A1 (de) 2006-07-03 2008-01-10 Conti Temic Microelectronic Gmbh Identifikationssystem
US8454993B2 (en) 2007-11-23 2013-06-04 Lupin Limited Controlled release pharmaceutical compositions of pregabalin

Also Published As

Publication number Publication date
HU230031B1 (hu) 2015-05-28
WO2011107812A2 (en) 2011-09-09
WO2011107812A3 (en) 2011-11-10
MA34090B1 (fr) 2013-03-05
HU1000120D0 (en) 2010-04-28
CN102869350A (zh) 2013-01-09
EP2542229A2 (en) 2013-01-09
EA201290856A1 (ru) 2013-02-28
US8968780B2 (en) 2015-03-03
EA021719B1 (ru) 2015-08-31
HUP1000120A2 (en) 2011-09-28
US20130064893A1 (en) 2013-03-14
ZA201207375B (en) 2014-03-26
BR112012022255A2 (pt) 2016-10-25

Similar Documents

Publication Publication Date Title
UA106907C2 (uk) Стабілізована фармацевтична композиція
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
UA104869C2 (uk) Фармацевтичні композиції, що містять ліганди рецептора дофаміну
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
WO2012075492A3 (en) Carbocycle-substituted purine and 7-deazapurine compounds
GT201300165A (es) Compuestos y su uso como inhibidores de bace
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
NZ599880A (en) Use of bethanechol for treatment of xerostomia
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MY156434A (en) Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2009004908A (es) Compuestos quimicos.
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
WO2012048129A3 (en) Inhibitors of polo-like kinase
MX2015001917A (es) Composiciones farmaceuticas de memantina.
WO2010127143A3 (en) Neuroprotective ganoderma compositions and methods of use
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
HK1206347A1 (en) Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors
HK1206348A1 (en) Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors
MX2010008706A (es) Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.